None listed
Conditions
Interventions
Dietary Supplement : Subjects will be randomized to receive GCB50 (Eclonia cava enzymatic extracts) 4mg or placebo. Subjects will orally self-adminster Eclonia cava enzymatic extracts or placebo bid,
Sponsors
Dong Il Pharmtek
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Subjects who agree the particpation in the trial and submit informed and consent before the beginning of the trial. 2) Male and female subjects between 20-60years of age inclusive 3)BMI of 25.0-29.9kg/m2
Exclusion criteria
Exclusion criteria: 1)The Patients with severe cerebrovascular disease, cardiac disease (If that patient's clinical status is stable, they can participate in the clinical trial according to investgator) 2) The patient who take the medicine that can affect the state of weight change (uptake inhibitors, appetite suppressant, Antipsychotics hydragogue, contraceptives, steroid, and female sex hormon) within recent 1 months. 3) subject for uncontrolled hypertension, diabetes mellitus, thyroid disease (If that patient's clinical status is stable, they can participate in the clinical trial in the sight of investigator). 4)Serum creatinine = 2 times the upper limit of normal. 5)Serum AST(Aspartate aminotransferase)/ALT(Alanine aminotransferase) = 3 times the upper limit of normal. 6) Subjects who complain gastrointestinal symptoms such as heartburn, dyspepsia 7) Subjects with CNS(central nervous system) disorder(depressive disorder, schizophrenia, alcoholism, drug addiction). 8)Subjects with the musculoskeletal disorders or restricted physical activity. 9)Allergy or hypersensitivity in the Ecklonia cava 10) Participation in commercial diet program within the 3 months prior to screening. 11)Participation in any clinical trail within the 1 month prior to screening or have a plan to participate in other clinical trial. 12)Woman who are pregnant of lactating or planning to pregnant 13)Subjects which in the opinion investigator could affect preclude evluation of response
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Chainge in fat percentage(by Dual Energy X-Ray Absorptiometry, DEXA) ;Waist circumference, Hip circumference, waist-hip ratio(WHR) ;Fat mass, Fat Free Mass(by Dual Energy X-Ray Absorptiometry, DEXA) | — |
Secondary
| Measure | Time frame |
|---|---|
| Body weight , Body mass index(BMI) ;Mesenteric fat area, Subcutaneous fat area, Total abdominal fat area, Mesenteric fat area/Subcutaneous fat area(by CT) ;Blood Lipid;Adiponectin, Leptin, hs-CRP | — |
Countries
Korea, Republic of
Contacts
Public ContactJae Kang
Inje University Seoul Paik Hospital
Outcome results
None listed